MedPath

CHOICE OF SUBJECTIVE OCULAR REFRACTION TECHNIQUE AND CORNEAL TOPOGRAPHY OF KERATOCONUS

Not Applicable
Completed
Conditions
Alteration of Visual Acuity
Keratoconus
Registration Number
NCT04174209
Lead Sponsor
University Hospital, Clermont-Ferrand
Brief Summary

Keratoconus is a rare evolving corneal ectasia that alters visual acuity. To improve spectacle-corrected visual acuity, various subjective refraction techniques can be used.

The subjective refraction techniques of keratoconus-carrying patients have never been studied.

The main hypothesis is that the most suitable subjective ocular refraction method varies with the corneal topography of the keratoconus.

The main objective is to define the most appropriate refractive technique(s) based on corneal topographies in order to provide keratoconus-affected patients with the best spectacle-corrected visual acuity.

Detailed Description

Keratoconus is a rare evolving corneal ectasia that alters visual acuity. To improve spectacle-corrected visual acuity, various subjective refraction techniques can be used. The Jackson Cylinder Cross Method, the Astigmatic Dial Technique and the Stenopeic Slit are three validated subjective refraction techniques for measuring astigmatism. The subjective refraction techniques of keratoconus-carrying patients have never been studied.

The main hypothesis is that the most suitable subjective ocular refraction method varies with the corneal topography of the keratoconus.

The investigators collect several characteristics of corneal topography of the keratoconus : the average value of the keratometry of the 3 central mm called Km ; the value of the point corresponding to the maximum keratometry (called Kmax), the distance between the center and the point of Kmax, (called d_Kmax) ; the corneal surface variance index called ISV ; the Belin/Ambrósio Enhanced Ectasia Display (called BAD-D).

The main objective is to define the most appropriate refractive technique(s) based on corneal topographies in order to provide keratoconus-affected patients with the best spectacle-corrected visual acuity.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
52
Inclusion Criteria
  • adult persons
  • patients with keratoconus
  • patients with alteration of visual acuity
  • ability to give informed consent to participate in the study
  • affiliation to a social security scheme
Exclusion Criteria
  • Keratoconus grafted with cornea or with intracorneal rings.
  • Central corneal opacities.
  • Presence of other eye diseases affecting visual acuity.
  • Patients under guardianship, curatorship or justice protection.
  • Pregnant or breastfeeding women.
  • Refusal to participate in the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Measure of keratometry (Km)day 1

average value of the keratometry of the 3 central mm called Km

Measure of the Belin/Ambrósio Enhanced Ectasia Display (BAD-D)day 1

Measure of the Belin/Ambrósio Enhanced Ectasia Display (BAD-D)

Measure of index of surface varaianceday 1

measure of the corneal surface variance index called ISV

Measure of the maximum keratometryday 1

value of the point corresponding to the maximum keratometry (called Kmax),

Measure d_Kmaxday 1

Measure of the distance between the center and the point of Kmax, (called d_Kmax)

Secondary Outcome Measures
NameTimeMethod
ametropia valueday 1

The values of the final corrective spheres (myopia or hyperopia).

Subsequent modification of the eyeglasses by the opticianday 30

The need (yes / no) for the optician to modify the prescribed spectacle lens (due to poor tolerance)

astigmatism axisday 1

Collection of the astigmatism axis given by each method, by the autorefractometer and by the corneal topography

possible methodday 1

The impossibility (yes / no) of carrying out each of the 3 refraction methods.

Trial Locations

Locations (1)

Chu Clermont Ferrand

🇫🇷

Clermont-Ferrand, France

Chu Clermont Ferrand
🇫🇷Clermont-Ferrand, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.